XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Restatement of Previously Issued Unaudited Condensed Financial Statements (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Restatement of Previously Issued Unaudited Condensed Financial Statements                  
Research and development expenses $ 13,837,650     $ 4,123,538     $ 29,885,874 $ 10,307,142  
Prepaid assets and other current assets 3,868,164     5,131,337     3,868,164 5,131,337 $ 7,644,376
Accrued expenses and other current liabilities 1,638,499     680,830     1,638,499 680,830 $ 3,737,285
Operating expenses 14,863,271     6,484,837     34,592,687 17,710,959  
Net loss $ (14,716,616) $ (9,537,122) $ (9,737,181) (6,431,951) $ (5,936,386) $ (5,234,063) $ (33,990,919) (17,602,400)  
Timing of accruals for research and development expenses                  
Restatement of Previously Issued Unaudited Condensed Financial Statements                  
Prepaid assets and other current assets       4,631,390       4,631,390  
Operating expenses       1,189,495       4,631,390  
Restatement Impacts                  
Restatement of Previously Issued Unaudited Condensed Financial Statements                  
Research and development expenses       (1,189,495)       (4,631,390)  
Prepaid assets and other current assets       4,631,390       4,631,390  
Operating expenses       (1,189,495)       (4,631,390)  
Net loss       1,189,495       4,631,390  
Restatement Impacts | Error Corrections Due to Expenses Recorded in Q3 2022                  
Restatement of Previously Issued Unaudited Condensed Financial Statements                  
Prepaid research and development expenses       1,320,321       $ 1,320,321  
Research and development expenses       $ 130,826